Davion Healthcare Plc (DAVI) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Davion Healthcare Plc (NASDAQ: DAVI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.68 (-37.55% 1D, market cap $67.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, DAVI ranks #353 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), DAVI carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SKIN (SkinHealth Systems Inc. (Class A)) holds a D- grade (36/100 RQD, P/E N/A, ROIC -26.9%, cap $66.0M) and LNSR (LENSAR Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $73.3M). Among the 5-stock peer group, DAVI leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).
For Davion Healthcare Plc (DAVI), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #353 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0% FCF Margin ($1.9M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While DAVI currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.00) and Max Pain ($1.76) forces dealer call-delta covering toward $3.37.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Davion Healthcare Plc (DAVI) dropped -37.55% to $1.68, trading at 2% of its 52-week range ($2.62 – $3.21). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity Therapeutics
First in a planned programme of acquisitions to expand Davion’s revenues, earnings and healthcare operationsDUBLIN, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Davion Healthcare Plc (NASDAQ: DAVI) (“Davion” or the “Group”), a deve
Ultra Clean shares surged 14.6% after beating earnings and sales estimates; Ultralife soared 143.8% on a $320M acquisition deal.
Acquisition adds battery-free smart wound dressing and two-minute multi-marker screening test to Davion’s growing healthcare portfolioDUBLIN, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Davion Healthcare Plc (Nasdaq: DAVI) ("Davio
Davion Healthcare Plc (NASDAQ:DAVI) ("Davion" or the "Company"), a next-generation digital healthcare company developing proprietary health monitoring technologies, today announces that it has completed
Davion Healthcare Plc ("Davion" or the "Company"), a next-generation digital healthcare company developing proprietary, non-invasive health monitoring technologies, today announces that its ordinary shares are expected t
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DAVI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DAVI. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Davion Healthcare Plc (DAVI) ranks #353 by composite RQD confidence (47/100, grade D) and #712 by equity capitalization ($67.3M). Within this direct 5-issuer industry benchmark cohort, DAVI leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. DAVI currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DAVI
ACTIVE
Davion Healthcare Plc | D | 47/100 | — | — | — | -37.55% | $67.3M | Benchmark Subject |
| SKIN SkinHealth Systems Inc. (Class A) | D- | 36/100 | — | 65.3% | -26.9% | -2.07% | $66.0M | /skin-vs-davi → |
| LNSR LENSAR Inc. | E | 24/100 | — | 39.4% | -35.0% | -2.18% | $73.3M | /lnsr-vs-davi → |
| QTEX QTREX Quantum Ltd. | E | 31/100 | — | 0.7% | -35.0% | -7.58% | $73.9M | /qtex-vs-davi → |
| MBOT Microbot Medical Inc. | D- | 41/100 | — | — | -15.8% | -2.68% | $75.2M | /mbot-vs-davi → |
Davion Healthcare Plc (DAVI) operates in Medical/Dental Instruments (Health Care) with an equity capitalization of $67.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-02, Davion Healthcare Plc (NASDAQ: DAVI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.68 (-37.55% 1D, market cap $67.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, DAVI ranks #353 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), DAVI carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SKIN (SkinHealth Systems Inc. (Class A)) holds a D- grade (36/100 RQD, P/E N/A, ROIC -26.9%, cap $66.0M) and LNSR (LENSAR Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $73.3M). Among the 5-stock peer group, DAVI leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).
For Davion Healthcare Plc (DAVI), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #353 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
DAVI last traded at $1.68 (-37.55% on volume of 1,401,894 shares), positioning the stock -44.00% below its 50-day simple moving average ($3.00) and -42.47% below its 200-day simple moving average ($2.92). Across its 52-week range of $2.62 to $3.21, DAVI sits at the 0.0% percentile with a 14-day RSI of 18.0 (OVERSOLD (<32)) and an implied next-earnings move of ±4.2% ($1.61 to $1.75).
Why DAVI Stock dropped -37.55% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).